Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
-
30.04.2020 A small hypoxia signature predicts response to neoadjuvant bevacizumab treatment
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
-
02.04.2020 Studienleitfaden für die COVID-19-Pandemie
Hinweise um die Patienten während der COVID-19-Pandemie in der klinischen Studie bestmöglich und protokollkonform zu behandeln.
-
24.03.2020 March 2020: Predefined surgical analysis of the randomized BrighTNess trial
We are pleased to inform you that the surgical results of the randomized BrighTNess trial have been published in JAMA Surgery.
-
12.03.2020 Hinweise bzgl Covid-19
DIe GBG beobachtet die Situation bzgl Coronavirus/Covid-19 und trifft entsprechende Vorbereitungen.
-
28.02.2020 February 2020: Long-term follow-up results of the IBIS-II trial
We are delighted to inform you that the long-term follow-up results of the randomized IBIS-II trial have been published in Lancet.
-
01.02.2020 January 2020: A combination of trastuzumab with tailored dose-dense adjuvant chemotherapy reduces risk of relapse in HER2-positive breast cancer
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
-
20.01.2020 Save the date: ESMO Breast Cancer 2020
ESMO Breast Cancer 2020 will take place on 7-9 May 2020 in Berlin, Germany.
-
01.01.2020 December 2019: HLA class I evaluation in breast cancer patients from GeparTrio trial
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
-
12.12.2019 SABCS 2019: Effects of capecitabine in neo-/adjuvant chemotherapy
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
-
11.12.2019 MammaMia Patientenkongress 2020
MammaMia! Patientenkongress Gynäkologische Krebserkrankungen am 2. Februar in Frankfurt.
-
06.12.2019 GBG presentations at SABCS
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
-
29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
-
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
-
21.10.2019 ESMO 2019 Congress: Merit Award
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
-
30.09.2019 Save the date: GBG-Jahrestreffen 2020
Das GBG-Jahrestreffen 2020 findet vom 27.-28. Februar in Frankfurt statt.
-
30.09.2019 Save the date: AGO State of the Art Meeting
Das AGO-Mamma State of the Art Meeting 2020 findet am 29. Februar in Frankfurt statt.
-
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
-
18.09.2019 TAXIS (GBG101) – 1ste Patientin in Deutschland
Am 17. September 2019 wurde die 1ste Patientin in die TAXIS-Studie eingeschlossen.
-
17.09.2019 GBG Forschung beim ESMO 2019
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
